drug development
Toward Targeted Therapies for Autoimmune Disorders
Toward Targeted Therapies for Autoimmune Disorders
Lawrence Steinman | Jun 1, 2016
Training the immune system to cease fire on native tissues could improve outcomes for autoimmune patients, but clinical progress has been slow.
Pfizer Scoops Anacor for $5.3 Billion
Pfizer Scoops Anacor for $5.3 Billion
Bob Grant | May 18, 2016
The acquisition-hungry pharmaceutical firm is purchasing the California-based eczema gel maker.
Another Fatal-Disease Drug in Limbo
Another Fatal-Disease Drug in Limbo
Jef Akst | Apr 26, 2016
A federal advisory panel votes against Sarepta Therapeutics’s treatment for Duchenne muscular dystrophy.
First Data from Anti-Aging Gene Therapy
First Data from Anti-Aging Gene Therapy
Kerry Grens | Apr 25, 2016
A biotech company reports that an experimental treatment elongated its CEO’s telomeres. 
Zooming In on an Antidepressant Target
Zooming In on an Antidepressant Target
Ruth Williams | Apr 6, 2016
Structural studies reveal how SSRI drugs bind to the human serotonin transporter.
Another Drug Price Hike
Another Drug Price Hike
Bob Grant | Mar 28, 2016
Valeant Pharmaceuticals is criticized for jacking up the price of a drug used in assisted suicide.
Cannabis-Based Drug for Epilepsy
Cannabis-Based Drug for Epilepsy
Jef Akst | Mar 14, 2016
A marijuana-derived compound shows continued success in treating children with a rare form of the seizure disorder. 
Things That Go Bump
Things That Go Bump
Bob Grant | Mar 1, 2016
Scientists still don’t know why animals sleep or how to define the ubiquitous behavior.
Desperately Seeking Shut-Eye
Desperately Seeking Shut-Eye
Anna Azvolinsky | Mar 1, 2016
New insomnia drugs are coming on the market, but drug-free therapy remains the most durable treatment.
Shire to Buy Baxalta for $32 Billion
Shire to Buy Baxalta for $32 Billion
Tracy Vence | Jan 12, 2016
The Dublin-based pharma giant is set to acquire Baxalta, an Illinois-based Baxter spinoff, expanding its rare disease drug portfolio.